ESR1 and breast carcinoma: Taken together, our results demonstrate that miR-342 contributes not only to ERα expression but also to TAM response in breast cancer patients that result in prolonged survival, and implicate it to be a useful prognostic biomarker in ER-positive breast cancer patients.